Pharmacokinetics and Safety of Golimumab, a Fully Human Anti-TNF-α Monoclonal Antibody, in Subjects With Rheumatoid Arthritis-Reference-Cited by-同舟云学术

Pharmacokinetics and Safety of Golimumab, a Fully Human Anti-TNF-α Monoclonal Antibody, in Subjects With Rheumatoid Arthritis

Published:2007-03 Issue:3 Volume:47 Page:383-396
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:

Author:

Zhou Honghui,Jang Haishan,Fleischmann Roy M.,Bouman-Thio Esther,Xu Zhenhua,Marini Joseph C.,Pendley Charles,Jiao Qun,Shankar Gopi,Marciniak Stanley J.,Cohen Stanley B.,Rahman Mahboob U.,Baker Daniel,Mascelli Mary Ann,Davis Hugh M.,Everitt Daniel E.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference17 articles.

1. TNF alpha-a pivotal role in rheumatoid arthritis;Brennan;Br J Rheumatol,1992

2. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis;Santos Lacomba;Ophthalmic Res.,2001

3. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation;Braegger;Lancet,1992

4. TNF-alpha as a promising therapeutic target in chronic asthma: a lesson from rheumatoid arthritis;Russo;Clin Sci (Lond),2005

Cited by 166 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structural design of the anti-TNFα therapeutic NANOBODY® compound, ozoralizumab, to support its potent and sustained clinical efficacy;Biochemical and Biophysical Research Communications;2024-11

2. Predicting Human Subcutaneous Bioavailability of Therapeutic Monoclonal Antibodies from Systemic Clearance and Volume of Distribution;Molecular Pharmaceutics;2024-09-03

3. A Complete Sojourn of Monoclonal Antibodies: AI, Rare Diseases / Disorders and Immunotoxic Effects;Current Proteomics;2024-06

4. Anti-tumor necrosis factor α: originators <i>versus</i> biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies;Reumatismo;2023-12-19

5. Disease-modifying anti-rheumatic drugs associated with different diabetes risks in patients with rheumatoid arthritis;RMD Open;2023-07